- Home
- ANNX
ANNX
Annexon Inc.
as of 02-26-2026 3:38pm EST
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 730.4M | IPO Year: | 2020 |
| Target Price: | $16.50 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -1.08 | EPS Growth: | 42.94 |
| 52 Week Low/High: | $1.28 - $7.18 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -4.70 | Index: | N/A |
| Free Cash Flow: | -118021000.0 | FCF Growth: | N/A |
AI-Powered ANNX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Annexon Inc. (ANNX)
EVP & CHIEF FINANCIAL OFFICER
Avg Cost/Share
$5.11
Shares
7,851
Total Value
$40,118.61
Owned After
113,765
SEC Form 4
EVP & CHIEF BUSINESS OFFICER
Avg Cost/Share
$5.10
Shares
6,225
Total Value
$31,747.50
Owned After
124,464
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$5.10
Shares
5,290
Total Value
$26,979.00
Owned After
73,152
SEC Form 4
EVP & CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$5.10
Shares
5,290
Total Value
$26,979.00
Owned After
123,487
SEC Form 4
EVP & CHIEF INNOVATION OFFICER
Avg Cost/Share
$5.11
Shares
7,857
Total Value
$40,149.27
Owned After
97,227
SEC Form 4
Director
Avg Cost/Share
$5.02
Shares
4,115
Total Value
$20,657.30
Owned After
54,405
SEC Form 4
Director
Avg Cost/Share
$4.47
Shares
4,115
Total Value
$18,394.05
Owned After
54,405
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Lew Jennifer | ANNX | EVP & CHIEF FINANCIAL OFFICER | Feb 18, 2026 | Sell | $5.11 | 7,851 | $40,118.61 | 113,765 | |
| Overdorf Michael | ANNX | EVP & CHIEF BUSINESS OFFICER | Feb 18, 2026 | Sell | $5.10 | 6,225 | $31,747.50 | 124,464 | |
| Dananberg Jamie | ANNX | CHIEF MEDICAL OFFICER | Feb 18, 2026 | Sell | $5.10 | 5,290 | $26,979.00 | 73,152 | |
| ARTIS DEAN RICHARD | ANNX | EVP & CHIEF SCIENTIFIC OFFICER | Feb 18, 2026 | Sell | $5.10 | 5,290 | $26,979.00 | 123,487 | |
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Feb 18, 2026 | Sell | $5.11 | 7,857 | $40,149.27 | 97,227 | |
| Carson William H. | ANNX | Director | Dec 30, 2025 | Buy | $5.02 | 4,115 | $20,657.30 | 54,405 | |
| Carson William H. | ANNX | Director | Dec 1, 2025 | Buy | $4.47 | 4,115 | $18,394.05 | 54,405 | |
| Choi Jung | ANNX | Director | Dec 1, 2025 | Buy | $4.19 | 33,000 | $138,270.00 | 33,000 |
Compare ANNX vs Leading Stocks
See how ANNX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ANNX Annexon Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.